Immunovant Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-87.2M | $-75.3M | $-51.4M | $-58.7M | $-73.9M | $-59.4M | $-63.2M | $-47.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $80.0K | $64.0K | $58.0K | $56.0K | $53.0K | $54.0K | $49.0K | $46.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $13.5M | $9.7M | $10.2M | $10.5M | $10.7M | $7.5M | $8.9M | $8.2M |
| Net Cash from Operating Activities | $-76.2M | $-59.7M | $-47.1M | $-60.1M | $-47.4M | $-55.8M | $-46.4M | $-20.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $182.0K | $150.0K | $131.0K | $34.0K | $45.0K | $26.0K | $98.0K | $31.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-182.0K | $-150.0K | $-131.0K | $-34.0K | $-45.0K | $-26.0K | $-98.0K | $-31.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $686.0K | $1.5M | $469.8M | $148.0K | $890.0K | $233.0K | $70.6M | $0 |
| Net Change in Cash | $-75.4M | $-55.6M | $421.0M | $-60.0M | $-46.6M | $-56.1M | $26.8M | $-21.4M |
| Free Cash Flow | $-76.4M | $-59.8M | $-47.2M | $-60.1M | $-47.4M | $-55.8M | $-46.5M | $-20.2M |